Back to search

University of Ioannina

Η επίδραση των νεότερων βιολογικών-τροποποιητικών της νόσου αντιρευματικών φαρμάκων (DMARDs) στους παράγοντες κινδύνου για την εμφάνιση καρδιαγγειακής νόσου σε ασθενείς με ρευματοειδή αρθρίτιδα

Abstract

dc:description

Rheumatoid arthritis (RA) is a systemic inflammatory disease of unknown etiology that mainly affects the synovium. Methotrexate (MTX) is the cornerstone of treatment. If the goal of treatment is not achieved with csDMARDs (conventional synthetic disease modifying antirheumatic drugs), when there are poor prognostic factors, the addition of a bDMARD (biological DMARD) should be considered. Inflammation plays an important role in the onset and progression of the atherosclerotic process. The purpose of this study is to evaluate the effect of bDMARDs on risk factors for cardiovascular disease in Greek RA patients. The study was performed in the outpatient clinics of the rheumatology clinic of the University General Hospital of Ioannina. All patients met the ACR / EULAR 2010 classification criteria for the disease. Informed consent was obtained from both patients and controls and the study protocol was approved by the Institutional Ethics Committee. A total of 70 patients who met the above criteria were admitted. Thirty one healthy volunteers who were used as a control group before starting bDMARDs were also included. Upon admission to the study, all patients underwent: demographic data recording, physical examination-assessment of disease activity, complete laboratory test, imaging test-ultrasound of common carotid arteries. Patients were already receiving MTX or (Leflunomide) LFN and prednisone at constant doses throughout the study. They started taking a biological agent after a failure of clinical and laboratory improvement with a combination of at least two csDMARDs. Serum lipid levels of patients were measured at baseline, 3 months and 6 months after the initiation of the biological agent. The levels of HDL-C, TC, TG, LDL-C, ApoA1, ApoB, Lp(a), CRP, ESR were measured. Levels of anti-oxLDL (autoantibodies against oxidized LDL and cIMT (carotid intima-media thickness) were assessed before and 6 months after the administration of bDMARDs. In this study, it was observed that patients with RA are more likely to develop atherosclerosis even if they are under therapy with csDMARDs. Comparison with healthy controls revealed higher levels of cIMT and lower levels of total cholesterol and HDL-C cholesterol for the group of patients, which is associated with high disease activity. After initiation of a bDMARD and without hypolipidemic therapy, a more favorable lipid profile was observed, involving an increase in HDL-C and ApoA1 levels with a concomitant decrease in cIMT, which constitutes an index of subclinical atherosclerosis. The titer of anti-oxLDL was also reduced. After 6 months of follow-up, the two categories of biological agents (anti-TNF and non anti-TNF) had a similar effect on inflammatory markers, lipids and cIMT. In conclusion, hyperlipidemia as a modifiable cardiovascular risk factor is an attractive target for cardiovascular risk management in RA. Early intervention and control of disease activity using bDMARDs can reduce the risk of atherosclerosis and cardiovascular events.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Papamichail, Georgios
  • Παπαμιχαήλ, Γεώργιος

Subjects

dc:subject × 14

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/52632

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Papamichail, Georgios; Παπαμιχαήλ, Γεώργιος. Η επίδραση των νεότερων βιολογικών-τροποποιητικών της νόσου αντιρευματικών φαρμάκων (DMARDs) στους παράγοντες κινδύνου για την εμφάνιση καρδιαγγειακής νόσου σε ασθενείς με ρευματοειδή αρθρίτιδα. University of Ioannina, 2022. http://hdl.handle.net/10442/hedi/52632